InduPro

EpiBiologics

This company develops bispecific antibodies to degrade extracellular proteins for patients with cancer and autoimmune disorders.

ProtOS

This company develops artificial intelligence models to design de-novo proteins for the degradation of undruggable targets for the pharmaceutical and medical biotechnology industries.

UbiquiTx

This company develops a programmable protein modulation platform using artificial intelligence to create targeted therapies for pharmaceutical businesses and patients with complex diseases.

ProteoValent Therapeutics

This company develops targeted protein degrader therapies for cancer and haematology patients.

Nurix Therapeutics

This company develops targeted protein degradation therapies to treat patients with cancer and autoimmune diseases.

Protuoso Biosciences

This company develops multifunctional recombinant fusion proteins for pharmaceutical researchers and clinicians treating cardiometabolic, oncological and autoimmune diseases.

General Proximity

This biotechnology platform develops induced-proximity medicines for pharmaceutical partners to target proteins associated with cancer, neurodegeneration and cardiometabolic diseases.

Proxima

Proxima develops artificial intelligence models and structural data platforms to design proximity-based medicines for pharmaceutical and biotechnology companies.